Tre recombinase is an experimental enzyme that in lab tests has removed DNA inserted by HIV from infected cells. Through selective mutation, Cre recombinase which recognizes loxP sites are modified to identify HIV long terminal repeats (loxLTR) instead. As a result, instead of performing Cre-Lox recombination, the new enzyme performs recombination at HIV provirus sites.
The structure of Tre in complex with loxLTR has been resolved (PDB: 5U91), allowing for analyzing the roles of individual mutations.
References
- Sarkar, Indrani; Hauber, Ilona; Hauber, Joachim; Buchholz, Frank (2007). "HIV-1 proviral DNA excision using an evolved recombinase". Science. 316 (5833): 1912–15. Bibcode:2007Sci...316.1912S. doi:10.1126/science.1141453. PMID 17600219. S2CID 2437602.
- Hauber, Ilona; Hofmann-Sieber, Helga; Chemnitz, Jan; et al. (September 26, 2013). "Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice". PLOS Pathogens. 9 (9): e1003587. doi:10.1371/journal.ppat.1003587. PMC 3784474. PMID 24086129.
- Meinke, G; Karpinski, J; Buchholz, F; Bohm, A (19 September 2017). "Crystal structure of an engineered, HIV-specific recombinase for removal of integrated proviral DNA". Nucleic Acids Research. 45 (16): 9726–9740. doi:10.1093/nar/gkx603. PMC 5766204. PMID 28934476.
External links
- Minkel, JR (June 28, 2007). "Designer enzyme cuts HIV out of infected cells". Scientific American.
 | This genetics article is a stub. You can help Misplaced Pages by expanding it. |